0001396814-24-000088.txt : 20240703 0001396814-24-000088.hdr.sgml : 20240703 20240703185222 ACCESSION NUMBER: 0001396814-24-000088 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240628 FILED AS OF DATE: 20240703 DATE AS OF CHANGE: 20240703 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SLONIN JONATHAN CENTRAL INDEX KEY: 0001875723 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35060 FILM NUMBER: 241101262 MAIL ADDRESS: STREET 1: C/O PACIRA BIOSCIENCES, INC. STREET 2: 5401 WEST KENNEDY BOULEVARD, SUITE 890 CITY: TAMPA STATE: FL ZIP: 33609 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Pacira BioSciences, Inc. CENTRAL INDEX KEY: 0001396814 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 510619477 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5401 WEST KENNEDY BOULEVARD STREET 2: SUITE 890 CITY: TAMPA STATE: FL ZIP: 33609 BUSINESS PHONE: 813-553-6680 MAIL ADDRESS: STREET 1: 5401 WEST KENNEDY BOULEVARD STREET 2: SUITE 890 CITY: TAMPA STATE: FL ZIP: 33609 FORMER COMPANY: FORMER CONFORMED NAME: Pacira Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20101029 FORMER COMPANY: FORMER CONFORMED NAME: PACIRA INC DATE OF NAME CHANGE: 20080318 FORMER COMPANY: FORMER CONFORMED NAME: Blue Acquisition Corp DATE OF NAME CHANGE: 20070418 4 1 wk-form4_1720047136.xml FORM 4 X0508 4 2024-06-28 0 0001396814 Pacira BioSciences, Inc. PCRX 0001875723 SLONIN JONATHAN C/O PACIRA BIOSCIENCES, INC. 5401 WEST KENNEDY BOULEVARD, SUITE 890 TAMPA FL 33609 0 1 0 0 Chief Medical Officer 1 Common Stock 2024-06-28 5 A 0 E 437.271 24.319 A 99306.746 D Common Stock 2024-07-01 4 F 0 914 28.46 D 98392.746 D Common Stock 2024-07-02 4 S 0 2836 28.25 D 95556.746 D Represents shares of common stock acquired under the issuer's employee stock purchase plan in June 2024. Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. /s/ Kristen Williams, Attorney-in-Fact 2024-07-03